Home » Topics » Respiratory, BioWorld Science

Respiratory, BioWorld Science
RSS

Recombinant PAF-AH progresses to phase II for ARDS

June 24, 1997

New orally active oligopeptide antiallergic from Central Drug Res. Inst.

June 23, 1997

Orally active MDP derivative as lead for antiallergic compounds

June 23, 1997

Labopharm and Sepracor to develop new dosage forms of levalbuterol

June 20, 1997

PPL Therapeutics authorized to start phase II trials with transgenic product

June 18, 1997

Dainippon Ink presents new antiallergic/antiasthmatic agent

June 18, 1997

New asthma treatment now available in Canada

June 17, 1997

Milkhaus receives FDA approval to start phase II cystic fibrosis trial

June 17, 1997

IND for gene therapy for cystic fibrosis approved

June 13, 1997

NIH funds high-throughput screening in allergic inflammation and immunology by Cadus

June 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...